<p>Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - 获取免费报告) 首席财务官 Mark Ragosa 于 11 月 12 日星期三出售了 19,900 股该股票。股票以平均价格 $40.94 出售，总价值为 $814,706.00。交易后，首席财务官持有该公司 31,086 股股票，价值约为 $1,272,660.84。这笔交易代表其持股减少了 39.03%。该交易已在向 SEC 提交的文件中披露，具体内容可通过此链接查看。</p>
<p>Mark Ragosa 最近还进行了以下交易：</p>
<ul>
<li>在 10 月 28 日星期二，Mark Ragosa 出售了 100 股 Kiniksa Pharmaceuticals International 股票。这些股票以平均价格 $41.00 出售，总价值为 $4,100.00。</li>
</ul>
<h2>Kiniksa Pharmaceuticals International 股票上涨 0.1%</h2>
<p>在周五的午盘交易中，NASDAQ:KNSA 股票上涨 $0.03，达到 $40.32。该股票交易量为 264,948 股，而其平均交易量为 622,492 股。该公司的市值为 30.6 亿美元，市盈率为 89.60，贝塔值为 0.16。Kiniksa Pharmaceuticals International, plc 的一年低点为 $17.82，一年高点为 $42.05。该股票的 50 日简单移动平均线为 $37.85，200 日简单移动平均线为 $32.23。</p>
<p>Kiniksa Pharmaceuticals International (NASDAQ:KNSA - 获取免费报告) 最近于 10 月 28 日星期二发布了其财报。公司报告本季度每股收益为 $0.23，低于市场共识预期的 $0.31，差额为 ($0.08)。Kiniksa Pharmaceuticals International 的净利润率为 6.01%，股本回报率为 7.46%。该公司本季度的收入为 $1.8086 亿，低于市场共识预期的 $1.6664 亿。去年同期，该公司每股收益为 ($0.18)。公司的收入同比增长 61.2%。Kiniksa Pharmaceuticals International 已设定其 2025 财年的每股收益指导。分析师预计 Kiniksa Pharmaceuticals International, plc 本财年的每股收益将为 -0.55。</p>
<h2>机构资金流入和流出</h2>
<p>一些机构投资者最近对 KNSA 的持仓进行了调整。Cerity Partners LLC 在第一季度将其在 Kiniksa Pharmaceuticals International 的持股增加了 42.3%。Cerity Partners LLC 现在拥有 40,708 股该公司的股票，价值 $904,000，此前在上个季度购买了额外的 12,110 股。CWM LLC 在第一季度将其在 Kiniksa Pharmaceuticals International 的持仓增加了 867.4%。CWM LLC 现在拥有 22,114 股该公司的股票，价值 $491,000，此前在此期间购买了额外的 19,828 股。Victory Capital Management Inc. 在第一季度获得了 Kiniksa Pharmaceuticals International 的新股份，价值约为 $1,184,000。Knights of Columbus Asset Advisors LLC 在第一季度将其在 Kiniksa Pharmaceuticals International 的股份增加了 2.7%。Knights of Columbus Asset Advisors LLC 现在拥有 62,624 股该公司的股票，价值 $1,391,000，此前在上个季度购买了额外的 1,658 股。最后，Sound View Wealth Advisors Group LLC 在第一季度将其在 Kiniksa Pharmaceuticals International 的持股增加了 4.0%。Sound View Wealth Advisors Group LLC 现在拥有 14,657 股该公司的股票，价值 $326,000，此前在此期间购买了额外的 568 股。53.95% 的股票由机构投资者和对冲基金持有。</p>
<h2>分析师设定新目标价</h2>
<p>几位研究分析师最近对 KNSA 股票发表了评论。花旗集团将 Kiniksa Pharmaceuticals International 的目标价格从 $45.00 上调至 $50.00，并在 10 月 17 日星期五的报告中给予该股票 &#34;买入&#34; 评级。Wedbush 在 10 月 28 日星期二的研究报告中重申了 &#34;跑赢大盘&#34; 评级，并将 Kiniksa Pharmaceuticals International 的目标价格设定为 $48.00（上调自 $44.00）。富国银行将 Kiniksa Pharmaceuticals International 的目标价格从 $42.00 上调至 $45.00，并在 9 月 25 日星期四的研究报告中给予该公司 &#34;增持&#34; 评级。华尔街禅在 11 月 2 日星期日的报告中将 Kiniksa Pharmaceuticals International 的评级从 &#34;强力买入&#34; 下调至 &#34;买入&#34;。最后，杰富瑞金融集团在 7 月 29 日星期二的研究报告中将 Kiniksa Pharmaceuticals International 的目标价格从 $45.00 上调至 $54.00，并给予该公司 &#34;买入&#34; 评级。六位研究分析师对该股票给予了买入评级，两位分析师对该公司的股票给予了持有评级。根据 MarketBeat 的数据，Kiniksa Pharmaceuticals International 当前的平均评级为 &#34;适度买入&#34;，平均目标价格为 $52.00。</p>
<p><strong>获取我们关于 KNSA 的最新研究报告</strong></p>
<h2>关于 Kiniksa Pharmaceuticals International</h2>
<p>(获取免费报告)</p>
<p>Kiniksa Pharmaceuticals, Ltd. 是一家生物制药公司，专注于发现、收购、开发和商业化治疗药物，以满足全球面临重大未满足医疗需求的患者。其产品候选药物包括 ARCALYST，一种针对复发性心包炎的白细胞介素-1α 和白细胞介素-1β；Mavrilimumab，一种单克隆抗体抑制剂，已完成针对巨细胞动脉炎的 II 期临床试验；Vixarelimab，一种单克隆抗体，正在进行针对结节性瘙痒症的 2b 期临床试验；以及 KPL-404，一种 CD40-CD154 相互作用的单克隆抗体抑制剂，这是 B 细胞成熟、免疫球蛋白类别转换和 1 型免疫反应的关键 T 细胞共刺激信号。</p>
<h2>特色故事</h2>
<ul>
<li>五只我们认为比 Kiniksa Pharmaceuticals International 更好的股票</li>
<li>3 只股票可以保护您的投资组合免受冠状病毒传播的影响</li>
<li>如果您等待下跌，Micron Technology 可能会让您错失良机</li>
<li>房地产投资信托是否值得在您的投资组合中占有一席之地？</li>
<li>3 只悄然推动 AI 和科技革命的股票</li>
<li>顶级生物科技股票：探索创新机会</li>
<li>Jefferies 告诉 NVIDIA 让位，选择 Broadcom 作为顶级半导体股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S05TQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S05TQQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资 1,000 美元于 Kiniksa Pharmaceuticals International 吗？</h2>
<p>在您考虑 Kiniksa Pharmaceuticals International 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Kiniksa Pharmaceuticals International 并不在名单上。</p>
<p>虽然 Kiniksa Pharmaceuticals International 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

KNSA

<p>Kiniksa Pharmaceuticals International 的首席财务官 Mark Ragosa 出售了 19,900 股，减少了 39.03% 的持股比例。这些股票以每股 40.94 美元的价格出售，总计 814,706 美元。出售后，Ragosa 拥有 31,086 股，价值 1,272,660.84 美元。该交易已在 SEC 文件中披露。该公司的股票最近受到机构的关注，并且分析师进行了升级，多家机构提高了价格目标</p>

<p>Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) CFO Mark Ragosa sold 19,900 shares of the stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $40.94, for a total value of $814,706.00. Following the transaction, the chief financial officer owned 31,086 shares of the company's stock, valued at approximately $1,272,660.84. This trade represents a 39.03% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.</p>
<div class="lb-trans"><p>Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - 获取免费报告) 首席财务官 Mark Ragosa 于 11 月 12 日星期三出售了 19,900 股该股票。股票以平均价格 $40.94 出售，总价值为 $814,706.00。交易后，首席财务官持有该公司 31,086 股股票，价值约为 $1,272,660.84。这笔交易代表其持股减少了 39.03%。该交易已在向 SEC 提交的文件中披露，具体内容可通过此链接查看。</p>
</div><p>Mark Ragosa also recently made the following trade(s):</p>
<div class="lb-trans"><p>Mark Ragosa 最近还进行了以下交易：</p>
</div><ul>
<li>On Tuesday, October 28th, Mark Ragosa sold 100 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $41.00, for a total value of $4,100.00.</li>
</ul>
<div class="lb-trans"><ul>
<li>在 10 月 28 日星期二，Mark Ragosa 出售了 100 股 Kiniksa Pharmaceuticals International 股票。这些股票以平均价格 $41.00 出售，总价值为 $4,100.00。</li>
</ul>
</div><h2>Kiniksa Pharmaceuticals International Stock Up 0.1%</h2>
<div class="lb-trans"><h2>Kiniksa Pharmaceuticals International 股票上涨 0.1%</h2>
</div><p>Shares of NASDAQ:KNSA traded up $0.03 during mid-day trading on Friday, reaching $40.32. 264,948 shares of the stock were exchanged, compared to its average volume of 622,492. The company has a market cap of $3.06 billion, a P/E ratio of 89.60 and a beta of 0.16. Kiniksa Pharmaceuticals International, plc has a one year low of $17.82 and a one year high of $42.05. The stock's 50 day simple moving average is $37.85 and its 200-day simple moving average is $32.23.</p>
<div class="lb-trans"><p>在周五的午盘交易中，NASDAQ:KNSA 股票上涨 $0.03，达到 $40.32。该股票交易量为 264,948 股，而其平均交易量为 622,492 股。该公司的市值为 30.6 亿美元，市盈率为 89.60，贝塔值为 0.16。Kiniksa Pharmaceuticals International, plc 的一年低点为 $17.82，一年高点为 $42.05。该股票的 50 日简单移动平均线为 $37.85，200 日简单移动平均线为 $32.23。</p>
</div><p>Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last released its earnings results on Tuesday, October 28th. The company reported $0.23 EPS for the quarter, missing the consensus estimate of $0.31 by ($0.08). Kiniksa Pharmaceuticals International had a net margin of 6.01% and a return on equity of 7.46%. The firm had revenue of $180.86 million during the quarter, compared to the consensus estimate of $166.64 million. During the same quarter in the previous year, the firm posted ($0.18) EPS. The company's revenue was up 61.2% on a year-over-year basis. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. Analysts anticipate that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Kiniksa Pharmaceuticals International (NASDAQ:KNSA - 获取免费报告) 最近于 10 月 28 日星期二发布了其财报。公司报告本季度每股收益为 $0.23，低于市场共识预期的 $0.31，差额为 ($0.08)。Kiniksa Pharmaceuticals International 的净利润率为 6.01%，股本回报率为 7.46%。该公司本季度的收入为 $1.8086 亿，低于市场共识预期的 $1.6664 亿。去年同期，该公司每股收益为 ($0.18)。公司的收入同比增长 61.2%。Kiniksa Pharmaceuticals International 已设定其 2025 财年的每股收益指导。分析师预计 Kiniksa Pharmaceuticals International, plc 本财年的每股收益将为 -0.55。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>A number of institutional investors have recently made changes to their positions in KNSA. Cerity Partners LLC lifted its holdings in Kiniksa Pharmaceuticals International by 42.3% during the 1st quarter. Cerity Partners LLC now owns 40,708 shares of the company's stock valued at $904,000 after purchasing an additional 12,110 shares during the last quarter. CWM LLC raised its position in shares of Kiniksa Pharmaceuticals International by 867.4% in the first quarter. CWM LLC now owns 22,114 shares of the company's stock valued at $491,000 after purchasing an additional 19,828 shares during the period. Victory Capital Management Inc. acquired a new stake in shares of Kiniksa Pharmaceuticals International during the 1st quarter worth about $1,184,000. Knights of Columbus Asset Advisors LLC lifted its stake in shares of Kiniksa Pharmaceuticals International by 2.7% during the 1st quarter. Knights of Columbus Asset Advisors LLC now owns 62,624 shares of the company's stock worth $1,391,000 after buying an additional 1,658 shares during the last quarter. Finally, Sound View Wealth Advisors Group LLC boosted its holdings in shares of Kiniksa Pharmaceuticals International by 4.0% during the 1st quarter. Sound View Wealth Advisors Group LLC now owns 14,657 shares of the company's stock worth $326,000 after buying an additional 568 shares during the period. 53.95% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些机构投资者最近对 KNSA 的持仓进行了调整。Cerity Partners LLC 在第一季度将其在 Kiniksa Pharmaceuticals International 的持股增加了 42.3%。Cerity Partners LLC 现在拥有 40,708 股该公司的股票，价值 $904,000，此前在上个季度购买了额外的 12,110 股。CWM LLC 在第一季度将其在 Kiniksa Pharmaceuticals International 的持仓增加了 867.4%。CWM LLC 现在拥有 22,114 股该公司的股票，价值 $491,000，此前在此期间购买了额外的 19,828 股。Victory Capital Management Inc. 在第一季度获得了 Kiniksa Pharmaceuticals International 的新股份，价值约为 $1,184,000。Knights of Columbus Asset Advisors LLC 在第一季度将其在 Kiniksa Pharmaceuticals International 的股份增加了 2.7%。Knights of Columbus Asset Advisors LLC 现在拥有 62,624 股该公司的股票，价值 $1,391,000，此前在上个季度购买了额外的 1,658 股。最后，Sound View Wealth Advisors Group LLC 在第一季度将其在 Kiniksa Pharmaceuticals International 的持股增加了 4.0%。Sound View Wealth Advisors Group LLC 现在拥有 14,657 股该公司的股票，价值 $326,000，此前在此期间购买了额外的 568 股。53.95% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>Several research analysts recently commented on KNSA shares. Citigroup increased their target price on shares of Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the stock a &#34;buy&#34; rating in a report on Friday, October 17th. Wedbush restated an &#34;outperform&#34; rating and set a $48.00 price objective (up from $44.00) on shares of Kiniksa Pharmaceuticals International in a research note on Tuesday, October 28th. Wells Fargo &amp; Company lifted their target price on Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the company an &#34;overweight&#34; rating in a research report on Thursday, September 25th. Wall Street Zen lowered Kiniksa Pharmaceuticals International from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a report on Sunday, November 2nd. Finally, Jefferies Financial Group raised their price target on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a &#34;buy&#34; rating in a research note on Tuesday, July 29th. Six research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat, Kiniksa Pharmaceuticals International currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $52.00.</p>
<div class="lb-trans"><p>几位研究分析师最近对 KNSA 股票发表了评论。花旗集团将 Kiniksa Pharmaceuticals International 的目标价格从 $45.00 上调至 $50.00，并在 10 月 17 日星期五的报告中给予该股票 &#34;买入&#34; 评级。Wedbush 在 10 月 28 日星期二的研究报告中重申了 &#34;跑赢大盘&#34; 评级，并将 Kiniksa Pharmaceuticals International 的目标价格设定为 $48.00（上调自 $44.00）。富国银行将 Kiniksa Pharmaceuticals International 的目标价格从 $42.00 上调至 $45.00，并在 9 月 25 日星期四的研究报告中给予该公司 &#34;增持&#34; 评级。华尔街禅在 11 月 2 日星期日的报告中将 Kiniksa Pharmaceuticals International 的评级从 &#34;强力买入&#34; 下调至 &#34;买入&#34;。最后，杰富瑞金融集团在 7 月 29 日星期二的研究报告中将 Kiniksa Pharmaceuticals International 的目标价格从 $45.00 上调至 $54.00，并给予该公司 &#34;买入&#34; 评级。六位研究分析师对该股票给予了买入评级，两位分析师对该公司的股票给予了持有评级。根据 MarketBeat 的数据，Kiniksa Pharmaceuticals International 当前的平均评级为 &#34;适度买入&#34;，平均目标价格为 $52.00。</p>
</div><p><strong>Get Our Latest Research Report on KNSA</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 KNSA 的最新研究报告</strong></p>
</div><h2>About Kiniksa Pharmaceuticals International</h2>
<div class="lb-trans"><h2>关于 Kiniksa Pharmaceuticals International</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.</p>
<div class="lb-trans"><p>Kiniksa Pharmaceuticals, Ltd. 是一家生物制药公司，专注于发现、收购、开发和商业化治疗药物，以满足全球面临重大未满足医疗需求的患者。其产品候选药物包括 ARCALYST，一种针对复发性心包炎的白细胞介素-1α 和白细胞介素-1β；Mavrilimumab，一种单克隆抗体抑制剂，已完成针对巨细胞动脉炎的 II 期临床试验；Vixarelimab，一种单克隆抗体，正在进行针对结节性瘙痒症的 2b 期临床试验；以及 KPL-404，一种 CD40-CD154 相互作用的单克隆抗体抑制剂，这是 B 细胞成熟、免疫球蛋白类别转换和 1 型免疫反应的关键 T 细胞共刺激信号。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>特色故事</h2>
</div><ul>
<li>Five stocks we like better than Kiniksa Pharmaceuticals International</li>
<li>3 Stocks to Protect Your Portfolio from the Coronavirus Contagion</li>
<li>If You Wait for the Dip, Micron Technology Could Leave You Behind</li>
<li>Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?</li>
<li>3 Stocks Quietly Powering the AI and Tech Revolution</li>
<li>Top Biotech Stocks: Exploring Innovation Opportunities</li>
<li>Jefferies Tells NVIDIA to Step Aside, Picks Broadcom as Top Semiconductor Stock</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 Kiniksa Pharmaceuticals International 更好的股票</li>
<li>3 只股票可以保护您的投资组合免受冠状病毒传播的影响</li>
<li>如果您等待下跌，Micron Technology 可能会让您错失良机</li>
<li>房地产投资信托是否值得在您的投资组合中占有一席之地？</li>
<li>3 只悄然推动 AI 和科技革命的股票</li>
<li>顶级生物科技股票：探索创新机会</li>
<li>Jefferies 告诉 NVIDIA 让位，选择 Broadcom 作为顶级半导体股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S05TQQ" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=KNSA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Kiniksa Pharmaceuticals International Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1,000 美元于 Kiniksa Pharmaceuticals International 吗？</h2>
</div><p>Before you consider Kiniksa Pharmaceuticals International, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑 Kiniksa Pharmaceuticals International 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kiniksa Pharmaceuticals International wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Kiniksa Pharmaceuticals International 并不在名单上。</p>
</div><p>While Kiniksa Pharmaceuticals International currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Kiniksa Pharmaceuticals International 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Mark Ragosa 出售了 19,900 股 Kiniksa Pharmaceuticals International（纳斯达克代码：KNSA）的股票